EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2020-2869 10.17179/excli2020-2869 Doc1295 Letter to the editor Immune responses during neoadjuvant chemotherapy in triple negative breast cancer Ghallab Ahmed * 1 Forensic Medicine and Toxicology Department, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt *To whom correspondence should be addressed: Ahmed Ghallab, Forensic Medicine and Toxicology Department, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt, E-mail: ghallab@vet.svu.edu.eg 11 09 2020 2020 19 1295 1296 04 09 2020 10 09 2020 Copyright © 2020 Ghallab 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

This article is available from https://www.excli.de/vol19/excli2020-2869.pdf


Dear Editor,

Recently, Axelrod and colleagues analyzed immune-related gene expression changes in breast cancer before and after neoadjuvant chemotherapy (Axelrod et al., 2020[1]). The authors analyzed 83 breast cancer tissue specimens, among them 44 triple negative carcinomas. An interesting result was that upregulation of immune-related genes was associated with better prognosis in the triple negative breast carcinomas (Axelrod et al., 2020[1]). Moreover, the authors studied PD-1Hi CD8+ peripheral T-cells for a cytolytic gene signature. Expression of cytotoxic genes in the peripheral blood was associated with worse prognosis, which may be explained by persistent micrometastatic disease that finally leads to recurrence (Axelrod et al., 2020[1]).

Numerous studies have analyzed the association of breast cancer with outcome, including the spontaneous course of disease and response to chemotherapy (Sparano et al., 2018[16]; Wang et al., 2018[19]; Finak et al., 2008[6]; van de Vijver et al., 2002[18]; Kwa et al., 2017[9]). High levels of T-cell and also B-cell/plasma cell associated genes were observed in breast carcinomas with relatively good prognosis (Schmidt et al., 2008[12], 2012[13], 2018[14]; Heimes et al., 2017[7]) but also in other tumor types (Edlund et al., 2019[5]; Lohr et al., 2013[10]). In contrast, antioxidative genes (Cadenas et al., 2010[2]) and genes associated with proliferation (Siggelkow et al., 2012[15]; Hellwig et al., 2016[8]; Cadenas et al., 2014[3]) and lipid (Cadenas et al., 2019[4]) as well as glycerophospholipid (Marchan et al., 2017[11]; Stewart et al., 2012[17]) metabolism are linked to worse prognosis. The current study of Axelrod et al. (2020[1]) is of high interest, because the authors systematically analyzed tumor tissue before and after chemotherapy and clearly demonstrated the prognostic role of genes associated with better response.

Conflict of interest

The author declares no conflict of interest.

Axelrod ML Nixon MJ Gonzalez-Ericsson PI Bergman RE Pilkinton MA McDonnell WJ Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer Clin Cancer Res 2020 epub ahead of print 10.1158/1078-0432.CCR-19-3685 Available from: http://dx.doi.org/10.1158/1078-0432.CCR-19-3685 Cadenas C Franckenstein D Schmidt M Gehrmann M Hermes M Geppert B Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer Breast Cancer Res 2010 12 R44 10.1186/bcr2599 Available from: http://dx.doi.org/10.1186/bcr2599 Cadenas C van de Sandt L Edlund K Lohr M Hellwig B Marchan R Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cell Cycle 2014 13 3282 3291 10.4161/15384101.2014.954454 Available from: http://dx.doi.org/10.4161/15384101.2014.954454 Cadenas C Vosbeck S Edlund K Grgas K Madjar K Hellwig B LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer Int J Cancer 2019 145 901 915 10.1002/ijc.32138 Available from: http://dx.doi.org/10.1002/ijc.32138 Edlund K Madjar K Mattsson JSM Djureinovic D Lindskog C Brunnström H Prognostic impact of tumor cell programmed death ligand 1 expression and immune cell infiltration in NSCLC J Thorac Oncol 2019 14 628 640 10.1016/j.jtho.2018.12.022 Available from: http://dx.doi.org/10.1016/j.jtho.2018.12.022 Finak G Bertos N Pepin F Sadekova S Souleimanova M Zhao H Stromal gene expression predicts clinical outcome in breast cancer Nat Med 2008 14 518 527 10.1038/nm1764 Available from: http://dx.doi.org/10.1038/nm1764 Heimes AS Madjar K Edlund K Battista MJ Almstedt K Elger T Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer Breast Cancer Res Treat 2017 165 293 300 10.1007/s10549-017-4327-0 Available from: http://dx.doi.org/10.1007/s10549-017-4327-0 Hellwig B Madjar K Edlund K Marchan R Cadenas C Heimes AS Epsin family member 3 and ribosome-related genes are associated with late metastasis in estrogen receptor-positive breast cancer and long-term survival in non-small cell lung cancer using a genome-wide identification and validation strategy PLoS One 2016 11 e0167585 10.1371/journal.pone.0167585 Available from: http://dx.doi.org/10.1371/journal.pone.0167585 Kwa M Makris A Esteva FJ Clinical utility of gene-expression signatures in early stage breast cancer Nat Rev Clin Oncol 2017 14 595 610 10.1038/nrclinonc.2017.74 Available from: http://dx.doi.org/10.1038/nrclinonc.2017.74 Lohr M Edlund K Botling J Hammad S Hellwig B Othman A The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer Cancer Lett 2013 333 222 228 10.1016/j.canlet.2013.01.036 Available from: http://dx.doi.org/10.1016/j.canlet.2013.01.036 Marchan R Büttner B Lambert J Edlund K Glaeser I Blaszkewicz M Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma Cancer Res 2017 77 4589 4601 10.1158/0008-5472.CAN-16-2065 Available from: http://dx.doi.org/10.1158/0008-5472.CAN-16-2065 Schmidt M Böhm D von Törne C Steiner E Puhl A Pilch H The humoral immune system has a key prognostic impact in node-negative breast cancer Cancer Res 2008 68 5405 5413 10.1158/0008-5472.CAN-07-5206 Available from: http://dx.doi.org/10.1158/0008-5472.CAN-07-5206 Schmidt M Hellwig B Hammad S Othman A Lohr M Chen Z A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors Clin Cancer Res 2012 18 2695 2703 10.1158/1078-0432.CCR-11-2210 Available from: http://dx.doi.org/10.1158/1078-0432.CCR-11-2210 Schmidt M Weyer-Elberich V Hengstler JG Heimes AS Almstedt K Gerhold-Ay A Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population Breast Cancer Res 2018 20 1 15 10.1186/s13058-018-0942-x Available from: http://dx.doi.org/10.1186/s13058-018-0942-x Siggelkow W Boehm D Gebhard S Battista M Sicking I Lebrecht A Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients BMC Cancer 2012 12 562 10.1186/1471-2407-12-562 Available from: http://dx.doi.org/10.1186/1471-2407-12-562 Sparano JA Gray RJ Makower DF Pritchard KI Albain KS Hayes DF Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer N Engl J Med 2018 379 111 121 10.1056/NEJMoa1804710 Available from: http://dx.doi.org/10.1056/NEJMoa1804710 Stewart JD Marchan R Lesjak MS Lambert J Hergenroeder R Ellis JK Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis Proc Natl Acad Sci U S A 2012 109 8155 8160 10.1073/pnas.1117654109 Available from: http://dx.doi.org/10.1073/pnas.1117654109 van de Vijver MJ He YD van't Veer LJ Dai H Hart AA Voskuil DW A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002 347 1999 2009 10.1056/NEJMoa021967 Available from: http://dx.doi.org/10.1056/NEJMoa021967 Wang S Beeghly-Fadiel A Cai Q Cai H Guo X Shi L Gene expression in triple-negative breast cancer in relation to survival Breast Cancer Res Treat 2018 171 199 207 10.1007/s10549-018-4816-9 Available from: http://dx.doi.org/10.1007/s10549-018-4816-9